Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer

NCT ID: NCT00126568

Last Updated: 2018-01-19

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-06-30
• Study Completion Date: 2011-09-30

Brief Summary

This phase II trial is studying how well sorafenib works in treating patients with advanced anaplastic thyroid cancer. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Detailed Description

OBJECTIVES:

I. Determine whether the objective response rate is ≥ 20% in patients with advanced anaplastic thyroid cancer treated with sorafenib.

II. Determine the survival of patients treated with this drug. III. Determine the safety profile of this drug in these patients. IV. Determine the pharmacokinetic predictors of response to this drug in these patients.

OUTLINE: This is a multicenter study.

Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed for survival.

Conditions

Anaplastic Thyroid Cancer; Recurrent Thyroid Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment (sorafenib tosylate)

Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Group Type: EXPERIMENTAL

sorafenib tosylate

Intervention Type: DRUG

Given orally

Interventions

sorafenib tosylate

Given orally

Intervention Type: DRUG

Other Intervention Names

BAY 43-9006; BAY 43-9006 Tosylate Salt; BAY 54-9085; Nexavar; SFN

Eligibility Criteria

Inclusion Criteria

• Performance status:

• ECOG 0-2 OR Karnofsky 50-100%
• Life expectancy more than 8 weeks
• Absolute neutrophil count >= 1,250/mm3
• Platelet count >= 100,000/mm3
• No evidence of bleeding diathesis
• Bilirubin =< 1.5 times upper limit of normal (ULN)
• PTT =< 1.5 times ULN
• Creatinine =< 1.5 times ULN
• No myocardial infarction within the past 6 months
• No New York Heart Association class III or IV cardiac disease
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No uncontrolled hypertension (i.e., systolic blood pressure (BP) > 150 mm Hg OR diastolic BP > 100 mm Hg)
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Able to swallow oral medication
• No history of allergic reactions attributed to compounds of similar chemical or biological composition to sorafenib
• No ongoing or active infection
• No psychiatric illness or social situation that would preclude study compliance
• No other invasive malignancy within the past 5 years except nonmelanoma skin cancer
• No other uncontrolled illness
• No more than 2 prior systemic cytotoxic chemotherapy regimens (combined modality systemic cytoxic chemotherapy is considered 1 prior cytotoxic regimen)
• At least 7 days since prior chemotherapy and recovered
• At least 7 days since prior radiotherapy and recovered
• No prior sorafenib or other inhibitors of MAP kinase signaling intermediates
• No prior cancer treatment that would preclude study participation
• No concurrent combination antiretroviral therapy for HIV-positive patients
• No other concurrent investigational agents
• No concurrent cytochrome P450 enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, or phenobarbital)
• No concurrent Hypericum perforatum (St. John's wort) or rifampin
• No concurrent therapeutic anticoagulation (concurrent prophylactic anticoagulation (i.e., low-dose warfarin) for venous or arterial access devices allowed provided requirements for INR and PTT are met)
• No other concurrent anticancer therapy
• Histologically confirmed anaplastic* thyroid cancer

• Not amenable to definitive curative surgery or radiotherapy [Note: *Papillary, follicular, or other histologies that are mixed or identified in a diagnostic tissue sample are allowed provided a high-grade undifferentiated anaplastic component is present ]
• No cardiac arrhythmia
• AST and ALT =< 3.5 times ULN
• INR < 2.0

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Panayiotis Savvides

Role: PRINCIPAL_INVESTIGATOR

Case Western Reserve University

Locations

Case Western Reserve University

Cleveland, Ohio, United States

Countries

United States

References

Savvides P, Nagaiah G, Lavertu P, Fu P, Wright JJ, Chapman R, Wasman J, Dowlati A, Remick SC. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid. 2013 May;23(5):600-4. doi: 10.1089/thy.2012.0103. Epub 2013 Apr 18.

Reference Type: DERIVED

PMID: 23113752 (View on PubMed)

Other Identifiers

NCI-2009-00118

Identifier Type: REGISTRY

Identifier Source: secondary_id

CASE 5304

Identifier Type: -

Identifier Source: secondary_id

CDR0000437789

Identifier Type: -

Identifier Source: secondary_id

CASE 5304

Identifier Type: OTHER

Identifier Source: secondary_id

7037

Identifier Type: OTHER

Identifier Source: secondary_id

U01CA062502

Identifier Type: NIH

Identifier Source: secondary_id

View Link

NCI-2009-00118

Identifier Type: -

Identifier Source: org_study_id